Elicio Therapeutics (ELTX) Change in Cash (2020 - 2026)

Elicio Therapeutics has reported Change in Cash for 7 years, with the latest figure at -$3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 1605.42% year-over-year to -$3.6 million; the trailing twelve-month figure through Mar 2026 stood at -$4.1 million (down 162.49% YoY), and the FY2025 full-year result was -$225000.0, down 104.33% from the prior year.
• Change in Cash for Q1 2026 stood at -$3.6 million, down from -$2.0 million in the prior quarter.
• The five-year high for Change in Cash was $23.5 million in Q3 2024, with the low at -$15.8 million in Q1 2022.
• Historically, Change in Cash has averaged $329941.2 across 5 years, with a median of -$1.1 million in 2024.
• Annual changes were most pronounced in 2024 — Change in Cash surged 555.03% — and 2026, when it plunged 1605.42%.
• Elicio Therapeutics' Change in Cash stood at $3.8 million in 2022, then tumbled by 176.06% to -$2.9 million in 2023, then sank by 194.92% to -$8.5 million in 2024, then jumped by 76.03% to -$2.0 million in 2025, then sank by 76.59% to -$3.6 million in 2026.
• The last three Change in Cash figures came in at -$3.6 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.